Treatment with verapamil during and after an acute myocardial infarction : a review based on the danish verapamil infarction trials I and II

The effect of verapamil on death and reinfarction after an acute myocardial infarction was studied in two double-blind, randomized, placebo-controlled multicenter trials, the Danish Verapamil Infarction Trials I and II (DAVIT I and II). The studies demonstrated that verapamil 360 mg/day from the 2nd week after an acute myocardial infarction, prevented death and reinfarction. Meta-analyses of the results of DAVITs I and II resulted in a reduction of pooled ratios of 22% (95% confidence limits 1-37, p=0.04) for death, 21% (5-35, p=0.02) for first major events (first reinfarction or death), and 27% (6-43, p=0.02) for the first reinfarctions